A summary of the co-promote termination liability as of March 31, 2013 is as follows (in thousands):



Net present value of payments based on estimated future net Avinza product sales as of December 31, 2012	$	12,534
Assumed payments made by Pfizer or assignee	(853		)
Fair value adjustments	492
Total co-promote termination liability as of March 31, 2013	12,173
Less: current portion of co-promote termination liability as of March 31, 2013	4,257
Long-term portion of co-promote termination liability as of March 31, 2013	$	7,916